Addario Lung Cancer Medical Institute

Our Mission

We strive to make lung cancer a survivable disease.

Partnering with the most innovative minds from the world’s premier oncology research institutions, we provide funds, staff, and a team of experts to assist in launching and managing investigator-initiated trials.

As a 501c(3) nonprofit organization, we’re dedicated to forwarding research that can lead to new therapeutics, diagnostics, and a better understanding of lung cancer risk factors and resistance mechanisms.

Learn more

Explore Our Trials

Active Clinical Trials

We revolutionized remote, decentralized, observational biomarker trials that push the boundaries of discovery to drive the biggest impact in the most efficient way possible.
See what we're doing.
Past Trials

Our research has led to a new understanding of oncogene driver mutations and familial risk factors.
Take a look back.
Why Join a Trial

Lung cancer patients make everything we do possible. Learn more about clinical trials and the power of participation.
Here's how.

The ALCMI Approach to Lung Cancer Science

To maximize our impact and investment, we concentrate our research efforts on 5 areas of focus.

Young Lung Cancer

We’re committed to investigating genomic markers in people under 40.
Inheritable Disease

We seek to understand hereditary risk factors for lung cancer.
Resistance Mechanisms

We conduct resistance mechanism biomarker trials across oncogene populations.
Collaboration

We work with numerous commercial sponsors and patient advocacy groups.
Specimen Research

We maintain a biospecimen bank with more than 2,000 specimens available for study

Read about Our Trials

* Now Enrolling *

Help us learn more about inherited risk in lung cancer.

Our current study, INHERIT (Investigating Hereditary Risk in Thoracic Cancers), aims to understand better the genetic risk for developing lung cancer. Partnering with Dana-Farber Cancer Institute and GO2 for Lung Cancer, we're investigating why lung cancer sometimes runs in families. We're looking at genetics as well as environmental factors and how these may interact. We hope this information will ultimately improve lung cancer screening, prevention, and treatment.

This is just one of the ways we're working to make lung cancer a survivable disease.

Learn more

News From Our LinkedIn Feed

By The Numbers

We invest in lung cancer science.

We're funding critical lung cancer research and providing staffing and guidance to quickly get investigator-initiated trials up and running.

We're proud of our stats, and we're just getting started.

Become a Sponsor

Founded

2008
Completed Clinical Trials

23
Publication Citations and Downloads

13,659
Trial Participants

1,754
Partners and Sponsors

56

Peer-Reviewed, Published Studies

Our studies have led to numerous publications in the world’s most prestigious peer-reviewed oncology journals.

“My collaboration with ALCMI has been an exceptional experience. Their commitment to advancing lung cancer research is unmatched, and together, we’ve been able to accelerate our understanding of resistance mechanisms to targeted therapies and the development of new therapies for patients in need. ALCMI’s innovative approach and deep expertise have made a significant impact in bridging the gap between research and patient care, offering real hope to those facing lung cancer.”

— DR. BIAGIO RICCIUTI, DANA-FARBER CANCER INSTITUTE